SUPRAER ™ for High Dose-Rate Aerosol Drug Delivery of Labile Macromolecules

SUPRAER™

A platform technology comprising a new class of aerosol delivery system

SUPRAER™ generates a large aqueous aerosol of the active agent which is rapidly dried, concentrated and delivered on demand as a solid respirable aerosol of “pure” agent.   SUPRAER™ provides an output of >100 mg/minute of pure protein, 85% of this being within the respirable range. This technology excels where the delivery of large masses of labile agents are required to be delivered to the respiratory tract.

Features of SUPRAER-drug combination for high dose-rate aerosol delivery:

•  Targets the drug directly to the diseased lungs

•  Enables home treatment

•  Reduces the total dose administered compared to oral or IV

•  Reduces the potential side-effects and complications with long term IV administration

•  Reduces the cost of the drug and its administration

•  Increases patient and physician acceptance and compliance

•  Produces an expected improvement in therapeutic outcome

Applications

Aerosol delivery of biotherapeutics:-

•  proteins such as alpha-1 Antitrypsin

•  Surfactant

•  siRNA

•  vaccines

•  viral vectors.

•  liposomes

Drug Discovery

Toxicology

SARES™:   Small Animal Respiratory Exposure System

SARES™

   Designed to meet the rigorous demands of the

toxicology, safety pharmacology and drug discovery industries

SARES™ enables the measurement of respiratory, cardiac and autonomic responses to nose-only exposure of airborne agents in 12 rats. These measurements can be made in awake animals prior to, during and following acute exposure of the respiratory tract to aerosols or gases. The regional deposition of radiotagged aerosols can also be measured, as can body temperature and other physiological parameters of interest .

Applications

Drug discovery

Safety Pharmacology

Toxicology

AUGASOME Platform Technology

AUGASOME ™ An effective oligonucleotide transport and modification of gene expression carrier platform technology for clinical aerosol delivery.

AUGASOME is targeted to deliver sufficient physiologically active “genetic switches” with minimal toxicity in aerosol form in a rapid, safe and patient friendly manner. This will potentially enable pharmaceutical and biotechnology companies to access previously undruggable targets sites.

Advantages

• Enables aerosol route delivery, obviate the complexity of genetic materials delivery, such as siRNA, via the blood stream or directly injection into the target organs.
• Encapsulates genetic material, protect genetic material from physical and biochemical/enzymatic degradation
• improves endocytic activities for translocation and the residence time of the genetic materials in the lungs for uptake
• Minimizes interferon-like immunological responses
• preserves functional integrity with minimal toxicity to the cells
• economical to produce